Ranjit Nair

NewYork–Presbyterian Brooklyn Methodist Hospital — United States

Medicine · Health Sciences

25h-index2.9kcitations286works1.92yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lymphoma Diagnosis and Treatment(137), CAR-T cell therapy research(111), Chronic Lymphocytic Leukemia Research(55), CNS Lymphoma Diagnosis and Treatment(23), Viral-associated cancers and disorders(22)

Publications284 total

Germline variants and their role in the pathogenesis of immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS) in adult lymphoma patients
Blood·2025
Surovatamig (AZD0486), a CD19xCD3 T-cell engager (TCE), demonstrates high rate of minimal residual disease (MRD)–Negative complete responses in Relapsed/Refractory (R/R) diffuse large B-cell lymphoma (DLBCL), including in patients who previously progressed on CD20 TCE and CD19 CAR T-cell therapies
Blood·2025
Impact of extranodal sites of lymphoma on clinical outcomes after CD19 CAR T cell therapy
Blood·2025Open Access
A phase II investigator-initiated frontline trial of evorpacept (ALX148), lenalidomide and rituximab for high tumor burden indolent b-cell non-Hodgkin lymphoma
Blood·2025Open Access
Long-term clinical outcomes from the smart start trial: Rituximab, lenalidomide and ibrutinib in patients with newly diagnosed large B-cell lymphoma
Blood·2025Open Access
Acalabrutinib plus rituximab followed by brexucabtagene autoleucel for frontline treatment of high-risk Mantle Cell Lymphoma: The window-3 clinical trial
Blood·2025
Impact of DUSP22 and TP63 rearrangements in patients with ALK-negative ALCL treated with frontline BV-CH(E)P
Blood·2025
Three-year follow-up of the Phase 1 first-in-human study investigating surovatamig, a novel CD19xCD3 T-cell engager, in patients with Relapsed/Refractory (R/R) follicular lymphoma (FL)
Blood·2025
Impact of putative cell of origin on CD19+CAR-T outcomes in patients with large B-cell lymphoma
Blood·2025Open Access
PET imaging biomarkers predict survival in peripheral T-cell lymphoma: A systematic review and meta-analysis.
Blood·2025
Cytotoxic lymphoma assessment response (CLyAR): A harmonized, compartment-based consensus response assessment framework for cytotoxic T-cell lymphomas
Blood·2025
Single center updated analysis of patients with Relapsed/Refractory peripheral T-cell lymphoma treated with linperlisib.
Blood·2025
Sitosterolemia and Early Atherosclerosis: A Review of Genetic Mechanisms and Newer Diagnostic Methods
Cardiology in Review·2025Open Access
Large Cell Transformation of Mycosis Fungoides/Sezary Syndrome: Prognostic Factors and Outcomes
European Journal of Cancer·2025
RUPTURED CORDS: A "SHOCK"-ING TALE OF ENDOCARDITIS AND MITRAL MAYHEM
CHEST Journal·2025
Outcomes for Patients with Primary Thyroid Lymphoma Treated with Radiation Therapy
International Journal of Radiation Oncology*Biology*Physics·2025
ABCL-1113: Safety and Efficacy of AZD0486, a CD19 × CD3 T-Cell Engager, in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Clinical Lymphoma Myeloma & Leukemia·2025
POSTER: ABCL-1113 Safety and Efficacy of AZD0486, a CD19 × CD3 T-Cell Engager, in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Clinical Lymphoma Myeloma & Leukemia·2025Open Access
Frontline acalabrutinib, lenalidomide and rituximab for advanced stage follicular lymphoma with high tumor burden: phase II trial
Nature Communications·2025· 1 citedOpen Access
Novel devimistat results in complete remissions in heavily pretreated Burkitt lymphoma in a phase 2 trial
Blood Advances·2025· 1 citedOpen Access
page 1 of 15Next →

Frequent Co-authors

Sattva S. Neelapu(32), Loretta J. Nastoupil(32), Jason R. Westin(31), Sairah Ahmed(29), Swaminathan P. Iyer(29), Raphaël Steiner(28), Hun Ju Lee(25), Paolo Strati(23), Michael Wang(22), Christopher R. Flowers(22), Luis Fayad(20), Felipe Samaniego(16), Maria Alma Rodriguez(15), Nathan Fowler(15), Chelsea C. Pinnix(13), Simrit Parmar(13), Elizabeth J. Shpall(12), Preetesh Jain(11), Misha Hawkins(10), Partow Kebriaei(10)